5-AMINOLAEVULINIC ACID (AS HYDROCHLORIDE) (Ameluz®)

Clinical Indication

Pre-treatment to photodynamic therapy for Actinic Keratosis, Bowen’s disease & superficial basal cell carcinoma.

Date of classification

April 2023

Red

Medicines which should be prescribed only in a specialist setting usually within a secondary or tertiary care service. NB: Some highly specialised RED medicines e.g. injectable treatments for cancer are not included on the LLR APC website list.